The role of neutrophils in cystic fibrosis

Current Opinion in Hematology

Volumn 21, Issue 1, 2014, Pages 16-22

  Gifford, Alison M ^a   Chalmers, James D ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

cystic fibrosis; cystic fibrosis transmembrane conductance regulator neutrophil elastase; neutrophils

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CD2 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ELUBRIXIN; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; OPSONIN; PENTRAXIN 3; RANTES; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; BRONCHIECTASIS; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; LUNG FUNCTION; MUCOCILIARY CLEARANCE; NEUTROPHIL; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; HUMANS; LEUKOCYTE ELASTASE; MACROLIDES; NEUTROPHILS; PROTEINASE INHIBITORY PROTEINS, SECRETORY;

EID: 84890553047     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000009     Document Type: Review

References (46)

1. Cohen TS, Prince A. Cystic fibrosis: A mucosal immunodeficiency syndrome. Nat Med 2012; 18:509-519.
2. Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: Molecular mechanisms and clinical implications. Thorax 2013. [Epub ahead of print]
3. Livraghi-Butrico A, Kelly EJ, Wilkinson KJ, et al. Loss of CFTR function exacerbates the phenotype of Na hyperabsorption in murine airways. Am J Physiol Lung Cell Mol Physiol 2013; 304:L469-L480. Murine data which suggest combined defects in both CFTR and ENaC produce more severe lung disease than either alone.
4. Hartl D, Gaggar A, Bruscia E, et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012; 11:363-382.
5. Witko-Sarsat V, Allen RC, Paulais M, et al. Disturbed myeloperoxidasedependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. J Immunol 1996; 157:2728-2735.
6. Corvol H, Fitting C, Chadelat K, et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2003; 284:L997-L1003.
7. Moriceau S, Lenoir G, Witko-Sarsat V. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide and roscovitine: Evidence for an innate neutrophil disturbance. J Innate Immun 2010; 2:260-266.
8. Zhou Y, Song K, Painter RG, et al. Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils. J Innate Immun 2013; 5:219-230. Evidence of the mechanism behind defective bacterial killing in CF neutrophils.
9. Bonvillain RW, Painter RG, Adams DE, et al. RNA interference against CFTR affects HL60-derived neutrophil microbicidal function. Free Radic Biol Med 2010; 49:1872-1880.
10. Montemurro P, Mariggiò MA, Barbuti G, et al. Increase in interleukin-8 production from circulating neutrophils upon antibiotic therapy in cystic fibrosis patients. J Cyst Fibros 2012; 11:518-524.
11. Houston N, Stewart N, Smith DS, et al. Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. J Cyst Fibros 2013; 12:352-362. Suggestion of different 'sub-populations' of neutrophils in the airway lumen and blood.
12. Laval J, Touhami J, Herzenberg LA, et al. Metabolic adaptation of neutrophils in cystic fibrosis airways involves distinct shifts in nutrient transporter expression. J Immunol 2013; 190:6043-6050. A further advance to our understanding of how the neutrophil adapts to the unique inflammatory environment of the CF lung.
13. Taggart C, Coakley RJ, Greally P, et al. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol 2000; 278:L33-L41.
14. Caldwell RA, Boucher RC, Stutts MJ. Neutrophil elastase activates near-silent epithelial Na channels and increased airway epithelial Na transport. Am J Physiol Lung Cell Mol Physiol 2005; 288:L813-L819.
15. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160:S49-S52.
16. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368:1963-1970. A significant finding, which suggests that neutrophil elastase activity in BAL fluid in early life is associated with the development of bronchiectasis and lung function decline in CF.
17. Laguna TA, Wagner BD, Starcher B, et al. Urinary desmosine: A biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 2012; 47:856-863. The development of urine desmosine as a marker of systemic elastin degradation promises to allow non-invasive assessment of neutrophil elastase activity.
18. Sagel SD, Wagner BD, Anthony MM, et al. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012; 186:857-865. Further evidence for neutrophil elastase as a biomarker in CF, predicting lung function decline.
19. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in noncystic fibrosis bronchiectasis. Mol Immunol 2013; 55: 27-34.
20. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration 2010; 80:59-70.
21. Fischer BM, Wong JK, Degan S. Increased expression of senescence markers in cystic fibrosis airways. Am J Physiol Lung Cell Mol Physiol 2013; 304:L394-L400. Evidence suggesting that neutrophil elastase can induce senescence in CF airway epithelial cells in vitro and perhaps in vivo.
22. Nordin SL, Jovic S, Kurut A, et al. High expression of midkine in the airways of patients with cystic fibrosis. Am J Respir Cell Mol Biol 2013. [Epub ahead of print]. Describes an epithelial derived antimicrobial elevated in the CF lung that is cleaved and inactivated by neutrophil elastase.
23. Do ring G, Frank F, Boudier C, et al. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 1995; 154:4842-4850.
24. Roghanian A, Drost EM, MacNee W, et al. Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. Am J Respir Crit Care Med 2006; 174:1189-1198.
25. Le Gars M, Descamps D, Roussel D, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2013; 187:170-179. Evidence that neutrophil elastase degrades wild-type and DF508-epithelial CFTR in vitro that has implications for other chronic lung diseases.
26. Chalmers JD, Smith MP, McHugh B, et al. Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012; 186:657-665.
27. Yipp BG, Petri B, Salina D, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med 2012; 18:1386-1393.
28. Akong-Moore K, Chow OA, von Kockritz-Blickwede M, Nizet V. Influences of chloride and hypochlorite on neutrophil extracellular trap formation. PloS One 2012; 7:e42984. Describes a potential link between CFTR and NET formation.
29. Dubois AV, Gauthier A, Bréa D, et al. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum. Am J Respir Cell Mol Biol 2012; 47:80-86. An important finding that DNA reduces the activity of neutrophil serine proteases, suggesting NETs function to limit protease induced damage.
30. Lau GW, Ran H, Kong F, et al. Pseudomonas aeruginosa pyocyanin is critical for lung infection in mice. Infect Immun 2004; 72:4275-4278.
31. Rada B, Jendrysik MA, Pang L, et al. Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. PLoS One 2013; 8:e54205. NET production induced by pyocyanin is a novel mechanism contributing to the immune dysfunction in CF.
32. Gray RD, Lucas CD, Mackellar A, et al. Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps. J Inflamm (Lond) 2013; 10:12.
33. Elborn JS, Perrett J, Forsman-Semb K, et al. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J 2012; 40:969-976. Phase IIa clinical study of a neutrophil elastase inhibitor in CF.
34. Stevens T, Ekholm K, Granse M, et al. AZD9668: Pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther 2011; 339:313-320.
35. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomised controlled trial. J Am Med Assoc 2003; 290:1749-1756.
36. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effects of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. J Am Med Assoc 2010; 303:1707-1715.
37. Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012; 142:1259-1266. Recent trial that updates information on the use of azithromycin in CF without P. aeruginosa showing improvement in lung function and markers of infection.
38. Tarran R, Sabater JR, Clarke TC, et al. Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. Am J Physiol Lung Cell Mol Physiol 2013; 304:L746-L756. Describes a novel macrolide anti-inflammatory with reduced antibacterial function.
39. Bensman TJ, Nguyen AN, Rao AP, Beringer PM. Doxycycline exhibits antiinflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther 2012; 25:377-382. In-vitro demonstration of the anti-inflammatory properties of doxycycline, reducing IL-8 and MMPs.
40. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13:1423-1430.
41. Moss RB, Mistry SJ, Konstan MW, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013; 12:241-248. An early stage trial of a CXCR2 inhibitor in cystic fibrosis.
42. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose binding lectin (MBL) insufficiency on the course of cystic fibrosis: A review and metaanalysis. Glycobiology 2011; 21:271-282.
43. Haerynck F, Van Steen K, Cattaert T, et al. Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. Hum Immunol 2012; 73:1175-1183. Interesting small study relating genetic deficiency in the opsonins ficolin-1 and ficolin-2 with P. aeruginosa colonization in CF.
44. Chiarini M, Sabelli C, Melotti P, et al. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 2010; 11:665-670.
45. Chalmers JD, McHugh BJ, Doherty CJ, et al. Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: A prospective study. Lancet Respir Med 2013; 1:175-274.
46. Paroni M, Moalli F, Nebuloni M, et al. Response of CFTR-deficient mice to long-term chronic Pseudomonas aeruginosa infection and PTX3 therapy. J Infect Dis 2013; 208:130-138.